Online citations, reference lists, and bibliographies.
← Back to Search

One Year Study Of Efficacy And Safety Of Infliximab In The Treatment Of Patients With Ocular And Neurological Behçet’s Disease Refractory To Standard Immunosuppressive Drugs

A. Giardina, A. Ferrante, F. Ciccia, M. Vadala', E. Giardina, G. Triolo
Published 2009 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
The aim of the study was to assess the long-term efficacy and safety of Infliximab therapy in the treatment of patients with Behçet’s disease refractory to standard immunosuppressive agents. Twenty-one patients that did not respond to corticosteroids and to at least one immunosuppressant (cyclosporin, methotrexate, azathioprine, cyclophosphamide) for the presence of ocular and/or CNS involvement were enrolled. Eighteen patients completed the study up to 54 weeks. Stable doses of prednisone (<10 mg/day) were permitted, immunosuppressants were discontinued at least 4 weeks prior baseline visit. The patients received three infusions of 5 mg/kg Infliximab (at weeks 0, 2 and 6) and then infusions of 5 mg/kg Infliximab every 8 weeks. At each visit data on clinical symptoms, response to therapy and adverse events were collected. The primary outcome of interest was to assess the clinical efficacy (total or partial recovery) of infliximab. Secondary end points were to evaluate quality of life and to monitor the safety of the drug. Eighteen patients achieved a total remission. Two patients achieved a partial remission and relapsed after 3 months from discontinuation of therapy. Infliximab was well tolerated throughout the study. A case of non-Hodgkin lymphoma was observed within 6 months. Minor side effects were headache, dizziness, tachycardia that regressed spontaneously and did not entail interruption. Anti-nuclear antibodies were not detected during the period of observation.
This paper references
10.1016/S0140-6736(02)80962-X
EPIDEMIC ERYSIPELAS.: ITS PROGRESS, CONTAGION, CHARACTER, AND TREATMENT
John Kilburn (1837)
10.1001/ARCHOPHT.1970.00990040453009
The rate of visual loss in Behçet's disease.
J. Mamo (1970)
10.1016/0140-6736(90)92643-v
[Criteria of diagnosis of Behcet's disease].
M. Hamza (1975)
[Behçet's disease].
G. M. van den Berg (1987)
10.1016/S0248-8663(05)82257-X
C 10 Recent epidemiological features of Behçet's disease in Japan
K. Nakae (1993)
Recent epidemiological features of Behçet ’ s disease in Japan
K Nakae (1993)
Risk factors for vital organ involvement in Behçet’s disease
N Dilsen (1993)
Cytokines in Behçet's disease.
N. Sayınalp (1996)
10.3349/YMJ.1997.38.6.411
Epidemiological features of Adamantiades-Behçet's disease in Germany and in Europe.
C. Zouboulis (1997)
10.3109/08830189709116845
Uveitis in Behçet's disease.
R. Nussenblatt (1997)
10.1093/RHEUMATOLOGY/38.8.728
Behçet's disease: evaluation of a new instrument to measure clinical activity.
B. Bhakta (1999)
10.1002/1529-0131(199909)42:9<1967::AID-ANR24>3.0.CO;2-Z
Th1 polarization of the immune response in Behçet's disease: a putative pathogenetic role of interleukin-12.
M. Frassanito (1999)
10.1136/gut.49.5.725
Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor α antibody
S. Travis (2001)
10.1053/GAST.2001.22556
Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report.
P. Hassard (2001)
10.1136/ARD.60.6.637
Remission of Behçet's syndrome with tumour necrosis factor α blocking therapy
P. Goossens (2001)
10.1016/S0140-6736(01)05497-6
Effect of infliximab on sight-threatening panuveitis in Behcet's disease
P. Sfikakis (2001)
EVect of inXiximab on sight-threatening panuveitis in Behcet’s disease
PP SWkakis (2001)
10.1136/ard.61.6.560
Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease
G. Triolo (2002)
10.1136/ard.61.5.459
Humoral and cell mediated immune response to cow's milk proteins in Behçet's disease
G. Triolo (2002)
10.1080/08830180212063
TH1 AND TH2 RESPONSES IN PATHOGENESIS AND REGULATION OF EXPERIMENTAL AUTOIMMUNE UVEORETINITIS
R. Caspi (2002)
10.1093/RHEUMATOLOGY/KEG453
The Behçet's disease activity index.
G. Lawton (2003)
10.1186/AR785
Vγ9/Vδ2 T lymphocytes in Italian patients with Behçet's disease: evidence for expansion, and tumour necrosis factor receptor II and interleukin-12 receptor β1 expression in active disease
G. Triolo (2003)
10.1007/BF02983787
Cytotoxic T-Cell Lymphoma Arising in Behçet Disease
Yukitaka Katsura (2003)
10.1136/ard.62.3.280
Anti-tumour necrosis factor α monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet’s syndrome
G. Licata (2003)
10.1016/J.AJO.2005.03.057
Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.
D. Jabs (2005)
10.1002/ART.21145
NF-kappaB protects Behçet's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins.
M. Todaro (2005)
NFkB protects Behçet’s disease T cells against CD95 induced apoptosis upregulating anti apoptotic proteins
M Todaro (2005)
10.1097/01.bor.0000197995.27579.9b
New approaches in the treatment of Adamantiades-Behçet's disease
N. Pipitone (2006)
10.1136/ARD.2005.044354
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
B. Combe (2006)
10.1002/art.23345
Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature.
N. Pipitone (2008)
10.1007/s00296-008-0606-8
Safety and efficacy of infliximab therapy in active behcet’s uveitis: an open-label trial
H. Alrayes (2008)
10.1136/ard.2007.080432
EULAR recommendations for the management of Behçet disease
G. Hatemi (2008)
Safety and eYcacy of inXiximab therapy in active Behçet’s uveitis: an openlabel study
H Al-Rayes (2008)
10.1007/s00393-008-0407-1
[EULAR recommendations for the management of Behçet's disease. Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)].
I. Kötter (2009)
InXiximab for the treatment of neuro-Beheçet’s disease: a case series and review of the literature
N Pipitone (2009)



This paper is referenced by
10.1016/j.phrs.2021.105593
Behçet disease: From pathogenesis to novel therapeutic options.
J. Rodríguez-Carrio (2021)
10.1007/978-3-030-55273-2_12
Treatment of Neuro-Behçet’s Disease
M. Kürtüncü (2021)
10.3389/fphar.2021.620340
The Efficacy and Safety of Infliximab in Refractory Noninfectious Uveitis: A Meta-Analysis of Observational Studies
(2021)
10.1007/s40674-020-00143-0
An Overview of Conventional and Recent Treatment Options for Behcet’s Disease
K. Cetin Gedik (2020)
10.1080/1744666X.2020.1798230
The current status of biological treatment for uveitis
C. Gaggiano (2020)
10.1016/j.jfo.2018.09.027
Œil et maladie de Behçet
I. Ksiaa (2019)
10.1016/J.CLINDERMATOL.2019.01.001
Behçet syndrome: A great imitator.
N. Akdeniz (2019)
10.1016/j.jfo.2019.02.002
Eye and Behçet's disease.
Imen Khairallah Ksiaa (2019)
10.1007/978-3-030-24131-5_20
Disease Management
Vedat Hamuryudan (2019)
10.14412/1995-4484-2019-133-141
New guidelines for the management of patients with Behcet's disease/syndrome (EULAR, 2018)
T. A. Lisitsyna (2019)
10.3389/fimmu.2019.02830
Treating the Different Phenotypes of Behçet's Syndrome
A. Bettiol (2019)
10.1016/j.clim.2019.108327
High-dose intravenous methylprednisolone in juvenile non-infectious uveitis: A retrospective analysis.
A. Schnabel (2019)
10.1007/s10067-018-4228-6
Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients
Claudia Fabiani (2018)
10.1093/rheumatology/key242
Management of major organ involvement of Behçet’s syndrome: a systematic review for update of the EULAR recommendations
Y. Ozguler (2018)
10.1136/annrheumdis-2018-213225
2018 update of the EULAR recommendations for the management of Behçet’s syndrome
G. Hatemi (2018)
10.1016/j.ophtha.2017.11.017
Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative.
A. Dick (2018)
10.3310/hta21680
A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults.
H. Squires (2017)
10.1016/J.EJR.2017.08.001
Efficacy of infliximab in refractory posterior uveitis in Behcet's disease patients
A. Garf (2017)
The Egyptian Rheumatologist
A. Garf (2017)
10.1007/s00415-017-8436-9
Neurological complications of Behçet’s syndrome
D. Kidd (2017)
10.1007/s40123-017-0115-5
A Review of the Landscape of Targeted Immunomodulatory Therapies for Non-Infectious Uveitis
Srilakshmi M Sharma (2017)
10.1097/MD.0000000000008045
Efficacy and safety of immunomodulatory drugs in patients with anterior uveitis
A. Gómez-Gómez (2017)
10.1016/j.ajo.2016.07.016
Anti-TNFα Treatment for HLA-B27-Positive Ankylosing Spondylitis-Related Uveitis.
Mirinae Kim (2016)
10.17116/jnevro20161166176-86
[Neurological and psychiatric disorders in Behҫet's disease].
P. Ovcharov (2016)
10.1016/J.REVMED.2014.07.008
Uvéites et biothérapies
E. Feurer (2015)
10.1016/j.jaut.2015.06.005
Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients.
H. Vallet (2015)
10.2147/OARRR.S46644
Update on the diagnosis and management of Behçet’s disease
R. Rokutanda (2014)
10.1097/IIO.0000000000000070
Clinical Trials in Noninfectious Uveitis
Jane S. Kim (2015)
10.2147/TCRM.S56163
Adalimumab in the management of Behçet’s disease
A. Ueda (2015)
10.4081/RR.2015.6115
Successful treatment of neuro-Behçet’s disease with infliximab: four years follow-up
M. Kaur (2015)
10.1007/s11739-013-1036-5
Behçet’s syndrome pathophysiology and potential therapeutic targets
G. Emmi (2014)
10.1002/14651858.CD010729.pub2
Biologics, colchicine, corticosteroids, immunosuppressants and interferon-alpha for Neuro-Behçet's Syndrome.
Francesca Nava (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar